NCT07178938View on ClinicalTrials.gov

Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2026

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2028

Conditions
Solid TumorsHER2-positive Breast Cancer
Interventions
DRUG

Radiotracer targeting SSTR2 ([68Ga]Ga-DOTA-TOC)

Patients will receive a single infusion of the diagnostic agent \[68Ga\]Ga-DOTA-TOC will which will be detected by PET/CT imaging. The recommended activity for an adult weighing 70 kg is 100 to 200 MBq, administered by direct slow intravenous injection and for a single use only.

All Listed Sponsors
lead

MedSIR

OTHER